Our CEO, J.D. Finley, highlighted the top five reasons why he believes the investment community and industry colleagues should pay attention to the Company in 2025. Watch his presentation at the Virtual Investor "Top 5 for ‘25” On-Demand Conference: https://bit.ly/4335BwH
Palisade Bio
制药业
Carlsbad，California 1,860 位关注者
Late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications
关于我们
Palisade Bio (Nasdaq: PALI) is a biopharmaceutical company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. The Company believes that addressing the disruption of the intestinal barrier can fundamentally change the way diseases are treated and establish new standards of patient care. Palisade Bio’s lead program, PALI-2108 is a microbiota-activated PDE4 inhibitor prodrug being developed for the treatment of moderate-to-severe ulcerative colitis and is advancing toward the completion of IND-enabling studies and an IND filing. The Company’s second lead program, PALI-1908, is being evaluated in preclinical development for the treatment of fibrostenotic Crohn’s Disease.
- 网站
-
https://www.palisadebio.com/
Palisade Bio的外部链接
- 所属行业
- 制药业
- 规模
- 11-50 人
- 总部
- Carlsbad，California
- 类型
- 私人持股
- 创立
- 2005
- 领域
- Therapeutics、Drug Development、Gastrobiome、Microbiome、Surgery、Cardiovascular、Gastrointestinal、Biotech、R&D和COVID-19
地点
-
主要
获取路线
7750 El Camino Real
Suite 2A
US，California，Carlsbad，92008
Palisade Bio员工
-
Mitchell L. Jones
Chief Medical Officer | MD Clinical Medicine and PhD Biomedical Engineering
-
William Fairchild
Founding member & Board member at Eppic Medical In
-
J.D. Finley
Chief Executive Officer at Palisade Bio, Inc.
-
Ryker Willie
Senior Vice President, Finance and Corporate Controller at Palisade Bio
动态
-
"This non-dilutive funding, which resulted from our pre-clinical studies previously conducted in Montreal under our co-development agreement with Giiant, bolsters our efforts to potentially bring a solution to patients,” said J.D. Finley, Chief Executive Officer of Palisade. Learn more: https://bit.ly/4i7BPuZ
-
Palisade today announced the receipt of CAD$1.39 million Canadian SR&ED credits for reimbursement of prior pre-clinical costs for PALI-2108 incurred under the Company’s joint development plan with Giiant. For more information: https://bit.ly/4i7BPuZ
-
Palisade Bio转发了
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand. Access it here: https://bit.ly/4aX9uoR Akari Therapeutics, Plc Autonomix Medical American Resources Corporation CNS Pharma enVVeno Medical Exxel Pharma GRI Bio, Inc. Kaida BioPharma Outlook Therapeutics, Inc. Palisade Bio TuHURA Biosciences #AKTX #AMIX #AREC #CNSP #NVNO #GRI #OTLK #PALI #HURA
-
Palisade Bio CEO, JD Finley, participated in the Virtual Investor "Top 5 for ‘25” On-Demand Conference. Watch the webcast here: https://bit.ly/434dEcy
-
In preclinical data presented at the 2025 Crohn’s and Colitis Congress, PALI-2108 was demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure. Palisade is advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts. Learn more: https://bit.ly/4aVrVKo
-
Learn about the poster titled “PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model" presented at the 2025 Crohn’s and Colitis Congress. View the poster here: https://bit.ly/4hPTdUW #UlcerativeColitis
-
Dr. Mitch Jones, Chief Medical Officer of Palisade, comments on the positive preclinical data presented at the 2025 Crohn’s and Colitis Congress and the potential of PALI-2108 for the treatment of #UlcerativeColitis. Read more: https://bit.ly/4aVrVKo
-
Palisade today announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug is in development for patients with #UlcerativeColitis. The data were presented at the 2025 Crohn’s and Colitis Congress. For key highlights: https://bit.ly/4aVrVKo
-
Attending the Crohn’s & Colitis Congress? Check out Palisade's poster presentation tomorrow, February 7th from 5:00 PM to 6:30 PM PST. Details: https://bit.ly/40RE0wQ